Related Experiment Videos

[Evolution of secondary prevention medication prescriptions after myocardial revascularisation: the ANCOR survey]

G Jullien1, M Mosnier, N Danchin

  • 1Merck Lipha Santé, 37, rue St-Romain, 69008 Lyon, France.

Annales De Cardiologie Et D'Angeiologie
|August 18, 2005
PubMed

Insights

The ANCOR survey found that myocardial revascularisation significantly increased secondary prevention medication prescriptions. Cardiologists now prioritize treating the underlying atherosclerotic disease alongside coronary artery blockages.

Area of Science:

  • Cardiology
  • Cardiovascular Medicine
  • Interventional Cardiology

Context:

  • Secondary prevention medication adherence post-myocardial revascularisation is crucial for long-term patient outcomes.
  • Understanding medication prescription trends is vital for optimizing cardiovascular disease management.
  • The ANCOR survey provides insights into current practices following coronary artery revascularisation procedures.

Purpose:

  • To assess the changes in secondary prevention medication prescriptions from pre- to post-myocardial revascularisation.
  • To identify factors influencing medication prescribing patterns in patients undergoing coronary procedures.
  • To evaluate the management of cardiovascular risk factors and symptoms after revascularisation.

Summary:

  • The ANCOR survey included 1535 patients (321 post-coronary surgery, 1214 post-percutaneous coronary intervention).
  • Significant increases in prescriptions for antiplatelet agents, beta-blockers, statins, ACE inhibitors, and nicorandil were observed post-procedure.
  • Despite treatment, a notable percentage of patients still experienced anginal symptoms, hypertension, or continued smoking, highlighting areas for improvement.

Impact:

  • Myocardial revascularisation serves as a critical juncture for enhancing secondary prevention strategies.
  • Cardiologists increasingly recognize the importance of managing the atherosclerotic process concurrently with focal coronary stenoses.
  • Findings may inform clinical guidelines and improve patient care by optimizing medication use and risk factor modification.

Related Concept Videos

Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Acute Coronary Syndrome III: Diagnostic Studies01:30

Acute Coronary Syndrome III: Diagnostic Studies

Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...